Document is current
Any future updates will be listed below
-
Authors
Pawlik, Piotr
Grigoriadis, Kristiana https://orcid.org/0000-0002-8435-0176
Bunkum, Abigail
Coggan, Helena
Frankell, Alexander M. https://orcid.org/0000-0002-0341-7878
Martinez-Ruiz, Carlos https://orcid.org/0000-0002-4817-0565
Karasaki, Takahiro https://orcid.org/0000-0001-6863-2360
Huebner, Ariana https://orcid.org/0000-0001-8009-4999
Rowan, Andrew
Fisher, Jasmin https://orcid.org/0000-0003-4477-9047
Hackshaw, Allan https://orcid.org/0000-0002-5570-5070
Swanton, Charles https://orcid.org/0000-0002-4299-3018
Zaccaria, Simone https://orcid.org/0000-0002-5265-7392
McGranahan, Nicholas https://orcid.org/0000-0001-9537-4045
- License Information
-
More Information
Article History
Received: 24 April 2024
Accepted: 11 July 2025
First Online: 13 August 2025
Competing interests
: A. Hackshaw has received fees for being a member of independent data monitoring committees for Roche-sponsored clinical trials and academic projects coordinated by Roche. N.M. holds patents related to determining human leukocyte antigen (HLA) LOH (PCT/GB2018/052004), determination of B cell fraction in mixed samples (PCT/EP2024/062999), determination of lymphocyte abundance in mixed samples (PCT/EP2022/070694), identifying responders to cancer treatment (PCT/GB2018/051912), targeting neoantigens (PCT/EP2016/059401), identifying patient response to immune checkpoint blockade (PCT/EP2016/071471) and predicting survival rates of patients with cancer (PCT/GB2020/050221) and has a patent pending in determining HLA disruption (PCT/EP2023/059039). C.S. acknowledges grant support from AstraZeneca, Boehringer-Ingelheim, Bristol Myers Squibb, Pfizer, Invitae (previously Archer Dx—collaboration in minimal residual disease sequencing technologies), Ono Pharmaceutical and Personalis; is chief investigator for the AZ MeRmaiD 1 and 2 clinical trials and is the Steering Committee chair; is co-chief investigator of the NHS Galleri trial financed by GRAIL and a paid member of GRAIL’s Scientific Advisory Board (SAB); receives consultant fees from Achilles (and is also an SAB member), Bicycle Therapeutics (SAB member and chair of Clinical Advisory Group), Genentech, Medicxi, China Innovation Centre of Roche (formerly Roche Innovation Centre, Shanghai), Metabomed (until July 2022), Relay Therapeutics (SAB member), Saga Diagnostics (SAB member) and the Sarah Cannon Research Institute; has received honoraria from Amgen, AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Illumina, MSD, Novartis and Pfizer; has previously held stock or options in GRAIL, has stock or options in Bicycle Therapeutics and Relay Therapeutics at present, and has stock and is co-founder of Achilles Therapeutics; declares patent applications for methods for lung cancer detection (PCT/US2017/028013, US20190106751A1), methods for targeting neoantigens (PCT/EP2016/059401), methods for identifying patient response to immune checkpoint blockade (PCT/EP2016/071471), methods for identifying patients who respond to cancer treatment (PCT/GB2018/051912), methods for determining HLA LOH (PCT/GB2018/052004), methods for predicting survival rates of patients with cancer (PCT/GB2020/050221), methods and systems for tumour monitoring (PCT/EP2022/077987), and methods for analysis of HLA allele transcriptional deregulation (PCT/EP2023/059039); and is an inventor on a European patent application (PCT/GB2017/053289) relating to assay technology to detect tumour recurrence (this patent has been licensed to a commercial entity, and under their terms of employment, C.S. is due a revenue share of any revenue generated from such licence(s)). A.M.F. is a co-inventor on a patent application to determine methods and systems for tumour monitoring (PCT/EP2022/077987). J.F. is a member of the SAB at DAiNA.
